HPC1
MCID: PRS097
MIFTS: 41

Prostate Cancer, Hereditary, 1 (HPC1)

Categories: Cancer diseases, Genetic diseases, Rare diseases, Reproductive diseases

Aliases & Classifications for Prostate Cancer, Hereditary, 1

MalaCards integrated aliases for Prostate Cancer, Hereditary, 1:

Name: Prostate Cancer, Hereditary, 1 56 73 29 54 6
Prostate Cancer 1 56 13
Prca1 56 73
Hpc1 56 73
Cancer, Prostate, Hereditary, Type 1 39
Familial Prostate Cancer 1 73
Prostate Cancer, Familial 71

Characteristics:

OMIM:

56
Inheritance:
autosomal dominant form


HPO:

31
prostate cancer, hereditary, 1:
Inheritance autosomal dominant inheritance


Classifications:



External Ids:

OMIM 56 601518
MeSH 43 D011471
UMLS 71 C2931456

Summaries for Prostate Cancer, Hereditary, 1

UniProtKB/Swiss-Prot : 73 Prostate cancer, hereditary, 1: A condition associated with familial predisposition to cancer of the prostate. Most prostate cancers are adenocarcinomas that develop in the acini of the prostatic ducts. Other rare histopathologic types of prostate cancer that occur in approximately 5% of patients include small cell carcinoma, mucinous carcinoma, prostatic ductal carcinoma, transitional cell carcinoma, squamous cell carcinoma, basal cell carcinoma, adenoid cystic carcinoma (basaloid), signet-ring cell carcinoma and neuroendocrine carcinoma.

MalaCards based summary : Prostate Cancer, Hereditary, 1, also known as prostate cancer 1, is related to prostate cancer and hyperparathyroidism 2 with jaw tumors. An important gene associated with Prostate Cancer, Hereditary, 1 is RNASEL (Ribonuclease L). The drugs Docetaxel and Sargramostim have been mentioned in the context of this disorder. Affiliated tissues include prostate, bone and breast, and related phenotypes are neoplasm and prostate cancer

More information from OMIM: 601518

Related Diseases for Prostate Cancer, Hereditary, 1

Graphical network of the top 20 diseases related to Prostate Cancer, Hereditary, 1:



Diseases related to Prostate Cancer, Hereditary, 1

Symptoms & Phenotypes for Prostate Cancer, Hereditary, 1

Human phenotypes related to Prostate Cancer, Hereditary, 1:

31
# Description HPO Frequency HPO Source Accession
1 neoplasm 31 HP:0002664
2 prostate cancer 31 HP:0012125

Symptoms via clinical synopsis from OMIM:

56
Oncology:
prostate cancer

Clinical features from OMIM:

601518

Drugs & Therapeutics for Prostate Cancer, Hereditary, 1

Drugs for Prostate Cancer, Hereditary, 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 27)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Docetaxel Approved, Investigational Phase 1, Phase 2 114977-28-5 148124
2
Sargramostim Approved, Investigational Phase 2 83869-56-1, 123774-72-1
3
Metronidazole Approved Phase 2 443-48-1 4173
4
Sunitinib Approved, Investigational Phase 2 557795-19-4, 341031-54-7 5329102
5
Metformin Approved Phase 2 657-24-9 14219 4091
6
Bicalutamide Approved Phase 2 90357-06-5 2375 56069
7
nivolumab Approved Phase 2 946414-94-4
8 Molgramostim Investigational Phase 2 99283-10-0
9 Tubulin Modulators Phase 1, Phase 2
10 Antimitotic Agents Phase 1, Phase 2
11 Samarium Sm-153 lexidronam Phase 2
12 Analgesics, Non-Narcotic Phase 2
13 Analgesics Phase 2
14 Vaccines Phase 2
15 Anti-Infective Agents Phase 2
16 Antiprotozoal Agents Phase 2
17 Anti-Bacterial Agents Phase 2
18 Immunologic Factors Phase 2
19 Antiparasitic Agents Phase 2
20 Protein Kinase Inhibitors Phase 2
21 Angiogenesis Inhibitors Phase 2
22 Androgens Phase 2
23 Hormone Antagonists Phase 2
24 Hormones Phase 2
25 Hypoglycemic Agents Phase 2
26 Androgen Antagonists Phase 2
27 Antineoplastic Agents, Immunological Phase 2

Interventional clinical trials:

(show all 12)
# Name Status NCT ID Phase Drugs
1 Phase I/II Trial of Samarium Sm-153 Lexidronam Combined With Docetaxel for Patients With Androgen-Independent Prostate Cancer Unknown status NCT00121095 Phase 1, Phase 2 Samarium Sm-153 lexidronam + Docetaxel
2 A Randomized Phase 2.5 Study of (153)Sm-EDTMP (Quadramet) With or Without a PSA/TRICOM Vaccine in Men With Androgen-Insensitive Metastatic Prostate Cancer Completed NCT00450619 Phase 2
3 A Phase II Study of SU011248 in Men With Advanced Prostate Cancer Completed NCT00299741 Phase 2 Sunitinib
4 Bicalutamide With or Without Metformin for Biochemical Recurrence in Overweight or Obese Prostate Cancer Patients (BIMET-1) Recruiting NCT02614859 Phase 2 Bicalutamide;Metformin and Bicalutamide
5 Nivolumab as a Non-Castrating Therapy for MMR-deficient and CDK12- Altered Prostate Cancer With PSA Recurrence After Local Therapy Recruiting NCT04019964 Phase 2 Nivolumab
6 Investigation of Protein Biomarkers of Prostate Cancer Completed NCT00323180
7 Whole-Body 3D T1-weighted MR Imaging Anatomical Sequences: GE mDixon vs FSE (View) Approaches in Prostate Cancer. Comparison of Diagnostic Performance of GE mDixon and FSE, for Bone and Node Staging in Patients With Prostate Cancer. Completed NCT03034070
8 Laparoscopic Radical Prostatectomy: A Registry and Database Completed NCT00169676
9 A Pilot Study to Determine the Prevalence of Osteoporosis in Patients With Advanced Prostate Cancer Treated With Hormonal Manipulation Completed NCT00124410
10 The Herlev Hospital Post Radiation Therapy for Localized Prostate Cancer Database for Sexual Side Effects Completed NCT02274350
11 Comprehensive Analysis of Hypoxia in Prostate Cancer: Diagnostic Markers and Prognostic Significance Recruiting NCT01191099
12 Effectiveness of a Web-based Intervention to Promote Health Screening in Men: A Community-based Randomised Controlled Trial Active, not recruiting NCT03583840

Search NIH Clinical Center for Prostate Cancer, Hereditary, 1

Genetic Tests for Prostate Cancer, Hereditary, 1

Genetic tests related to Prostate Cancer, Hereditary, 1:

# Genetic test Affiliating Genes
1 Prostate Cancer, Hereditary, 1 29 RNASEL

Anatomical Context for Prostate Cancer, Hereditary, 1

MalaCards organs/tissues related to Prostate Cancer, Hereditary, 1:

40
Prostate, Bone, Breast, Thyroid, Brain, Retina, Lung

Publications for Prostate Cancer, Hereditary, 1

Articles related to Prostate Cancer, Hereditary, 1:

(show top 50) (show all 111)
# Title Authors PMID Year
1
Germline mutations in the ribonuclease L gene in families showing linkage with HPC1. 6 56 54 61
11799394 2002
2
PCAP is the major known prostate cancer predisposing locus in families from south and west Europe. 56 61
11313747 2001
3
Combined analysis of hereditary prostate cancer linkage to 1q24-25: results from 772 hereditary prostate cancer families from the International Consortium for Prostate Cancer Genetics. 56 61
10712209 2000
4
Prostate cancer susceptibility locus HPC1 in Utah high-risk pedigrees. 56 61
10556291 1999
5
In Swedish families with hereditary prostate cancer, linkage to the HPC1 locus on chromosome 1q24-25 is restricted to families with early-onset prostate cancer. 61 56
10364525 1999
6
Linkage analysis of chromosome 1q markers in 136 prostate cancer families. The Cancer Research Campaign/British Prostate Group U.K. Familial Prostate Cancer Study Collaborators. 61 56
9497242 1998
7
Linkage analysis of 49 high-risk families does not support a common familial prostate cancer-susceptibility gene at 1q24-25. 61 56
9311739 1997
8
Prostate cancer susceptibility locus on chromosome 1q: a confirmatory study. 56 61
9214675 1997
9
A practice guideline from the American College of Medical Genetics and Genomics and the National Society of Genetic Counselors: referral indications for cancer predisposition assessment. 6
25394175 2015
10
Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genome-wide search. 56
8910276 1996
11
Genetic alterations in untreated metastases and androgen-independent prostate cancer detected by comparative genomic hybridization and allelotyping. 56
8674067 1996
12
[RNase L, a crucial mediator of innate immunity and other cell functions]. 61 54
18950583 2008
13
Mapping of the human RNASEL promoter and expression in cancer and normal cells. 54 61
16241858 2005
14
HPC1/RNASEL mediates apoptosis of prostate cancer cells treated with 2',5'-oligoadenylates, topoisomerase I inhibitors, and tumor necrosis factor-related apoptosis-inducing ligand. 54 61
15604285 2004
15
Effects of RNase L mutations associated with prostate cancer on apoptosis induced by 2',5'-oligoadenylates. 54 61
14583476 2003
16
Implications for RNase L in prostate cancer biology. 54 61
12590567 2003
17
Mouse acute leukemia develops independent of self-renewal and differentiation potentials in hematopoietic stem and progenitor cells. 61
30733302 2019
18
RNase L Suppresses Androgen Receptor Signaling, Cell Migration and Matrix Metalloproteinase Activity in Prostate Cancer Cells. 61
28257035 2017
19
Lung Cancer-Targeting Peptides with Multi-subtype Indication for Combinational Drug Delivery and Molecular Imaging. 61
28529640 2017
20
The Hsp72 and Hsp90α mRNA Responses to Hot Downhill Running Are Reduced Following a Prior Bout of Hot Downhill Running, and Occur Concurrently within Leukocytes and the Vastus Lateralis. 61
28747888 2017
21
Photo- and thermochromic and adsorption properties of porous coordination polymers based on bipyridinium carboxylate ligands. 61
26370743 2015
22
[Hereditary prostate cancer]. 61
24864115 2014
23
PAC1-expressing structures of neural retina alter their PAC1 isoform splicing during postnatal development. 61
24352804 2014
24
Genetic analysis of the principal genes related to prostate cancer: a review. 61
23141781 2013
25
Halobacterium piscisalsi Yachai et al. 2008 is a later heterotypic synonym of Halobacterium salinarum Elazari-Volcani 1957. 61
22058320 2012
26
Effects of hen production cycle and egg weight on egg quality and composition, hatchability, duckling quality, and first-week body weight in Pekin ducks. 61
22010253 2011
27
New insights into the role of RNase L in innate immunity. 61
21190483 2011
28
Contribution of HPC1 (RNASEL) and HPCX variants to prostate cancer in a founder population. 61
20564318 2010
29
Xenotropic murine leukemia virus-related virus establishes an efficient spreading infection and exhibits enhanced transcriptional activity in prostate carcinoma cells. 61
20015990 2010
30
Advances in biomarkers for the early diagnosis of prostate cancer. 61
20109357 2010
31
Single and multivariate associations of MSR1, ELAC2, and RNASEL with prostate cancer in an ethnic diverse cohort of men. 61
20086112 2010
32
[G138A polymorphism of the RNASEL gene and its association with the development of prostate cancer. Preliminary study]. 61
19961052 2009
33
A fragile site within the HPC1 region at 1q25.3 affecting RGS16, RGSL1, and RGSL2 in human breast carcinomas. 61
18521847 2008
34
Halobacterium piscisalsi sp. nov., from fermented fish (pla-ra) in Thailand. 61
18768619 2008
35
Analysis of the RNASEL/HPC1, and macrophage scavenger receptor 1 in Asian-Indian advanced prostate cancer. 61
18436282 2008
36
Pathological aggressiveness of prostatic carcinomas related to RNASEL R462Q allelic variants. 61
18289577 2008
37
A genome-wide association screen identifies regions on chromosomes 1q25 and 7p21 as risk loci for sporadic prostate cancer. 61
17876339 2008
38
A scientific journey through the 2-5A/RNase L system. 54
17681844 2007
39
Polycomb-group oncogenes EZH2, BMI1, and RING1 are overexpressed in prostate cancer with adverse pathologic and clinical features. 61
17134822 2007
40
Molecular biology in prostate cancer. 61
16648113 2006
41
Prevalent mutations in prostate cancer. 61
16267836 2006
42
Involvement of the RNAse L gene in prostate cancer. 61
16869093 2006
43
A transcriptional signaling pathway in the IFN system mediated by 2'-5'-oligoadenylate activation of RNase L. 61
16203993 2005
44
A transposon-based activation-tagging population in Arabidopsis thaliana (TAMARA) and its application in the identification of dominant developmental and metabolic mutations. 61
16087178 2005
45
Association of susceptibility alleles in ELAC2/HPC2, RNASEL/HPC1, and MSR1 with prostate cancer severity in European American and African American men. 61
15824169 2005
46
Loss of heterozygosity: an independent prognostic factor of colorectal cancer. 61
15682467 2005
47
A convenient and sensitive fluorescence resonance energy transfer assay for RNase L and 2',5' oligoadenylates. 54
16000857 2005
48
Genetic analysis of the RNASEL gene in hereditary, familial, and sporadic prostate cancer. 61
15534086 2004
49
Thyroid hormone regulation of prohormone convertase 1 (PC1): regional expression in rat brain and in vitro characterization of negative thyroid hormone response elements. 61
15291740 2004
50
The complex genetic epidemiology of prostate cancer. 61
14749351 2004

Variations for Prostate Cancer, Hereditary, 1

ClinVar genetic disease variations for Prostate Cancer, Hereditary, 1:

6 (show top 50) (show all 764) ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 RNASEL NM_021133.4(RNASEL):c.3G>A (p.Met1Ile)SNV Pathogenic 13005 rs74315365 1:182555939-182555939 1:182586804-182586804
2 RNASEL NM_021133.4(RNASEL):c.793G>T (p.Glu265Ter)SNV Conflicting interpretations of pathogenicity 13004 rs74315364 1:182555149-182555149 1:182586014-182586014
3 HOXB13 NM_006361.5(HOXB13):c.*160dupduplication Uncertain significance 691033 17:46803991-46803992 17:48726629-48726630
4 HOXB13 NM_006361.5(HOXB13):c.*155dupduplication Uncertain significance 691031 17:46803996-46803997 17:48726634-48726635
5 HOXB13 NM_006361.5(HOXB13):c.*153G>ASNV Uncertain significance 691030 17:46803999-46803999 17:48726637-48726637
6 HOXB13 NM_006361.5(HOXB13):c.*153deldeletion Uncertain significance 691029 17:46803999-46803999 17:48726637-48726637
7 HOXB13 NM_006361.5(HOXB13):c.*152G>CSNV Uncertain significance 691028 17:46804000-46804000 17:48726638-48726638
8 HOXB13 NM_006361.5(HOXB13):c.*151_*152insCinsertion Uncertain significance 691027 17:46804000-46804001 17:48726638-48726639
9 HOXB13 NM_006361.5(HOXB13):c.*149_*150insGinsertion Uncertain significance 691025 17:46804002-46804003 17:48726640-48726641
10 HOXB13 NM_006361.5(HOXB13):c.*149deldeletion Uncertain significance 691026 17:46804003-46804003 17:48726641-48726641
11 HOXB13 NM_006361.5(HOXB13):c.*148C>ASNV Uncertain significance 691024 17:46804004-46804004 17:48726642-48726642
12 HOXB13 NM_006361.5(HOXB13):c.*146T>GSNV Uncertain significance 691023 17:46804006-46804006 17:48726644-48726644
13 HOXB13 NM_006361.5(HOXB13):c.*146T>CSNV Uncertain significance 691022 17:46804006-46804006 17:48726644-48726644
14 HOXB13 NM_006361.5(HOXB13):c.*146deldeletion Uncertain significance 691021 17:46804006-46804006 17:48726644-48726644
15 HOXB13 NM_006361.5(HOXB13):c.*143deldeletion Uncertain significance 691230 17:46804009-46804009 17:48726647-48726647
16 HOXB13 NM_006361.5(HOXB13):c.*142C>ASNV Uncertain significance 691020 17:46804010-46804010 17:48726648-48726648
17 HOXB13 NM_006361.5(HOXB13):c.*140G>TSNV Uncertain significance 691019 17:46804012-46804012 17:48726650-48726650
18 HOXB13 NM_006361.5(HOXB13):c.*140G>CSNV Uncertain significance 691018 17:46804012-46804012 17:48726650-48726650
19 HOXB13 NM_006361.5(HOXB13):c.*138deldeletion Uncertain significance 691016 17:46804014-46804014 17:48726652-48726652
20 HOXB13 NM_006361.5(HOXB13):c.*138T>GSNV Uncertain significance 691017 17:46804014-46804014 17:48726652-48726652
21 HOXB13 NM_006361.5(HOXB13):c.*137C>TSNV Uncertain significance 691015 17:46804015-46804015 17:48726653-48726653
22 HOXB13 NM_006361.5(HOXB13):c.*137C>ASNV Uncertain significance 691014 17:46804015-46804015 17:48726653-48726653
23 HOXB13 NM_006361.5(HOXB13):c.*136G>CSNV Uncertain significance 691229 17:46804016-46804016 17:48726654-48726654
24 HOXB13 NM_006361.5(HOXB13):c.*135T>GSNV Uncertain significance 691013 17:46804017-46804017 17:48726655-48726655
25 HOXB13 NM_006361.5(HOXB13):c.*132G>CSNV Uncertain significance 691012 17:46804020-46804020 17:48726658-48726658
26 HOXB13 NM_006361.5(HOXB13):c.*132G>ASNV Uncertain significance 691011 17:46804020-46804020 17:48726658-48726658
27 HOXB13 NM_006361.5(HOXB13):c.*131deldeletion Uncertain significance 691008 17:46804021-46804021 17:48726659-48726659
28 HOXB13 NM_006361.5(HOXB13):c.*131T>CSNV Uncertain significance 691010 17:46804021-46804021 17:48726659-48726659
29 HOXB13 NM_006361.5(HOXB13):c.*131T>ASNV Uncertain significance 691009 17:46804021-46804021 17:48726659-48726659
30 HOXB13 NM_006361.5(HOXB13):c.*130C>ASNV Uncertain significance 691007 17:46804022-46804022 17:48726660-48726660
31 HOXB13 NM_006361.5(HOXB13):c.*129dupduplication Uncertain significance 691006 17:46804022-46804023 17:48726660-48726661
32 HOXB13 NM_006361.5(HOXB13):c.*126dupduplication Uncertain significance 691005 17:46804025-46804026 17:48726663-48726664
33 HOXB13 NM_006361.5(HOXB13):c.*121_*122insGinsertion Uncertain significance 691004 17:46804030-46804031 17:48726668-48726669
34 HOXB13 NM_006361.5(HOXB13):c.*120_*121insGinsertion Uncertain significance 691003 17:46804031-46804032 17:48726669-48726670
35 HOXB13 NM_006361.5(HOXB13):c.*119T>ASNV Uncertain significance 691002 17:46804033-46804033 17:48726671-48726671
36 HOXB13 NM_006361.5(HOXB13):c.*118dupduplication Uncertain significance 691001 17:46804033-46804034 17:48726671-48726672
37 HOXB13 NM_006361.5(HOXB13):c.*115dupduplication Uncertain significance 691000 17:46804036-46804037 17:48726674-48726675
38 HOXB13 NM_006361.5(HOXB13):c.*114C>ASNV Uncertain significance 690999 17:46804038-46804038 17:48726676-48726676
39 HOXB13 NM_006361.5(HOXB13):c.*110A>TSNV Uncertain significance 690998 17:46804042-46804042 17:48726680-48726680
40 HOXB13 NM_006361.5(HOXB13):c.*110A>GSNV Uncertain significance 690997 17:46804042-46804042 17:48726680-48726680
41 HOXB13 NM_006361.5(HOXB13):c.*108A>GSNV Uncertain significance 690995 17:46804044-46804044 17:48726682-48726682
42 HOXB13 NM_006361.5(HOXB13):c.*105_*108deldeletion Uncertain significance 690994 17:46804044-46804047 17:48726682-48726685
43 HOXB13 NM_006361.5(HOXB13):c.*103_*104deldeletion Uncertain significance 690993 17:46804048-46804049 17:48726686-48726687
44 HOXB13 NM_006361.5(HOXB13):c.*95G>TSNV Uncertain significance 691054 17:46804057-46804057 17:48726695-48726695
45 HOXB13 NM_006361.5(HOXB13):c.*93deldeletion Uncertain significance 691053 17:46804059-46804059 17:48726697-48726697
46 HOXB13 NM_006361.5(HOXB13):c.*90C>TSNV Uncertain significance 691052 17:46804062-46804062 17:48726700-48726700
47 HOXB13 NM_006361.5(HOXB13):c.*90C>GSNV Uncertain significance 691051 17:46804062-46804062 17:48726700-48726700
48 HOXB13 NM_006361.5(HOXB13):c.*88deldeletion Uncertain significance 691231 17:46804064-46804064 17:48726702-48726702
49 HOXB13 NM_006361.5(HOXB13):c.*86G>ASNV Uncertain significance 691050 17:46804066-46804066 17:48726704-48726704
50 HOXB13 NM_006361.5(HOXB13):c.*80G>CSNV Uncertain significance 691049 17:46804072-46804072 17:48726710-48726710

Cosmic variations for Prostate Cancer, Hereditary, 1:

9 (show top 50) (show all 7592)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM149310968 ZFHX3 prostate,NS,carcinoma,adenocarcinoma c.5893C>T p.Q1965* 16:72796789-72796789 21
2 COSM149331699 ZFHX3 prostate,NS,carcinoma,adenocarcinoma c.5114C>G p.S1705* 16:72797568-72797568 21
3 COSM149269669 ZFHX3 prostate,NS,carcinoma,adenocarcinoma c.3340C>T p.R1114* 16:72889839-72889839 21
4 COSM149281678 ZFHX3 prostate,NS,carcinoma,adenocarcinoma c.5650G>T p.E1884* 16:72797032-72797032 21
5 COSM149265910 ZFHX3 prostate,NS,carcinoma,adenocarcinoma c.8849G>A p.R2950H 16:72793833-72793833 21
6 COSM149307401 ZFHX3 prostate,NS,carcinoma,adenocarcinoma c.4819C>T p.Q1607* 16:72797863-72797863 21
7 COSM149287761 ZFHX3 prostate,NS,carcinoma,adenocarcinoma c.6445C>T p.R2149C 16:72796237-72796237 21
8 COSM149262752 ZFHX3 prostate,NS,carcinoma,adenocarcinoma c.3533C>A p.S1178* 16:72812035-72812035 21
9 COSM149314230 ZFHX3 prostate,NS,carcinoma,adenocarcinoma c.2728G>A p.E910K 16:72950957-72950957 21
10 COSM149278210 ZFHX3 prostate,NS,carcinoma,adenocarcinoma c.2986A>T p.K996* 16:72950699-72950699 21
11 COSM149292073 ZFHX3 prostate,NS,carcinoma,adenocarcinoma c.405C>G p.Y135* 16:72959741-72959741 21
12 COSM152021810 YES1 prostate,NS,carcinoma,adenocarcinoma c.575-1G>T p.? 18:745858-745858 21
13 COSM152022004 YES1 prostate,NS,carcinoma,adenocarcinoma c.119C>G p.S40* 18:756709-756709 21
14 COSM101975701 XPO1 prostate,NS,carcinoma,adenocarcinoma c.1711G>A p.E571K 2:61492337-61492337 21
15 COSM101977073 XPO1 prostate,NS,carcinoma,adenocarcinoma c.1259T>C p.M420T 2:61493040-61493040 21
16 COSM101976154 XPO1 prostate,NS,carcinoma,adenocarcinoma c.2468T>G p.F823C 2:61485808-61485808 21
17 COSM101979599 XPO1 prostate,NS,carcinoma,adenocarcinoma c.1384G>T p.V462F 2:61492915-61492915 21
18 COSM101981883 XPO1 prostate,NS,carcinoma,adenocarcinoma c.1098T>A p.F366L 2:61494041-61494041 21
19 COSM101978581 XPO1 prostate,NS,carcinoma,adenocarcinoma c.3101T>G p.F1034C 2:61478935-61478935 21
20 COSM86795132 XPC prostate,NS,carcinoma,adenocarcinoma c.2200G>A p.G734S 3:14148864-14148864 21
21 COSM91367724 WT1 prostate,NS,carcinoma,adenocarcinoma c.1501C>T p.R501C 11:32389111-32389111 21
22 COSM91367638 WT1 prostate,NS,carcinoma,adenocarcinoma c.994C>G p.Q332E 11:32416497-32416497 21
23 COSM91376184 WT1 prostate,NS,carcinoma,adenocarcinoma c.1108C>T p.R370C 11:32396398-32396398 21
24 COSM91381446 WT1 prostate,NS,carcinoma,adenocarcinoma c.1353C>A p.F451L 11:32392051-32392051 21
25 COSM98492529 WAS prostate,NS,carcinoma,adenocarcinoma c.847G>A p.D283N 23:48688369-48688369 21
26 COSM88303023 VHL prostate,NS,carcinoma,adenocarcinoma c.242C>A p.P81Q 3:10142089-10142089 21
27 COSM88299216 VHL prostate,NS,carcinoma,adenocarcinoma c.219G>C p.Q73H 3:10142066-10142066 21
28 COSM88294223 VHL prostate,NS,carcinoma,adenocarcinoma c.499C>T p.R167W 3:10149822-10149822 21
29 COSM85193879 U2AF1 prostate,NS,carcinoma,adenocarcinoma c.692C>T p.S231L 21:43093133-43093133 21
30 COSM130300971 TYK2 prostate,NS,carcinoma,adenocarcinoma c.698G>A p.R233H 19:10365830-10365830 21
31 COSM87235561 TWF2 prostate,NS,carcinoma,adenocarcinoma c.1050G>T p.*350Yext*41 3:52229034-52229034 21
32 COSM87038387 TSC2 prostate,NS,carcinoma,adenocarcinoma c.4388T>A p.I1463N 16:2084610-2084610 21
33 COSM87046748 TSC2 prostate,NS,carcinoma,adenocarcinoma c.472G>A p.E158K 16:2054431-2054431 21
34 COSM87032748 TSC2 prostate,NS,carcinoma,adenocarcinoma c.1385G>A p.R462H 16:2062995-2062995 21
35 COSM87040966 TSC2 prostate,NS,carcinoma,adenocarcinoma c.392C>A p.P131H 16:2054351-2054351 21
36 COSM85719651 TSC1 prostate,NS,carcinoma,adenocarcinoma c.3100G>T p.G1034C 9:132896630-132896630 21
37 COSM85726617 TSC1 prostate,NS,carcinoma,adenocarcinoma c.508G>T p.G170C 9:132923348-132923348 21
38 COSM85719697 TSC1 prostate,NS,carcinoma,adenocarcinoma c.439G>T p.G147W 9:132923417-132923417 21
39 COSM88663750 TP63 prostate,NS,carcinoma,adenocarcinoma c.1106A>G p.K369R 3:189868693-189868693 21
40 COSM88650394 TP63 prostate,NS,carcinoma,adenocarcinoma c.1147C>T p.H383Y 3:189869341-189869341 21
41 COSM88644684 TP63 prostate,NS,carcinoma,adenocarcinoma c.728G>A p.R243Q 3:189864380-189864380 21
42 COSM88646095 TP63 prostate,NS,carcinoma,adenocarcinoma c.448G>A p.A150T 3:189808395-189808395 21
43 COSM88653018 TP63 prostate,NS,carcinoma,adenocarcinoma c.490G>A p.A164T 3:189808437-189808437 21
44 COSM87931229 TP53 prostate,NS,carcinoma,adenocarcinoma c.313G>T p.G105C 17:7676056-7676056 21
45 COSM87898431 TP53 prostate,NS,carcinoma,adenocarcinoma c.451C>T p.P151S 17:7675161-7675161 21
46 COSM87898714 TP53 prostate,NS,carcinoma,adenocarcinoma c.844C>T p.R282W 17:7673776-7673776 21
47 COSM88010014 TP53 prostate,NS,carcinoma,adenocarcinoma c.604C>T p.R202C 17:7674927-7674927 21
48 COSM87954983 TP53 prostate,NS,carcinoma,adenocarcinoma c.823T>G p.C275G 17:7673797-7673797 21
49 COSM87961560 TP53 prostate,NS,carcinoma,adenocarcinoma c.461G>A p.G154D 17:7675151-7675151 21
50 COSM88075013 TP53 prostate,NS,carcinoma,adenocarcinoma c.703A>C p.N235H 17:7674260-7674260 21

Expression for Prostate Cancer, Hereditary, 1

Search GEO for disease gene expression data for Prostate Cancer, Hereditary, 1.

Pathways for Prostate Cancer, Hereditary, 1

GO Terms for Prostate Cancer, Hereditary, 1

Sources for Prostate Cancer, Hereditary, 1

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....